A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.

• Subjects with advanced or metastatic solid tumours who have completed treatment with first line therapy:

‣ Epithelial ovarian, fallopian tube, or peritoneal cancer

⁃ Hepatocellular carcinoma

⁃ Non-small cell lung cancer

⁃ Urothelial cancer

⁃ Microsatellite instability high solid tumours, other than the above indications

• Radiologic and/or biochemical evidence of disease progression

• Completion of pre-treatment tumour biopsy

• Must have measurable disease by RECIST v1.1

• Ambulatory with an ECOG 0-1

• Life expectancy ≥ 6 months

• Meet protocol-specified laboratory requirements